Immunotherapy Drugs Market

7500+ companies worldwide approach us every year for their revenue growth initiatives
Global top 2000 strategist rely on us for their growth strategies.
80% of fortune 2000 companies rely on our research to identify new revenue sources.
30000 High Growth Opportunities
95% renewal rate
KNOW MORE
  1. HOME
  2. Top Market Reports
  3. Immunotherapy Drugs Market

Immunotherapy Drugs Market Size, Share & Trends by Type (mAb, Checkpoint Inhibitor, Interferon, Cancer Vaccine), Application (Cancer, Autoimmune, Inflammatory, Hematology, Neurology), Route of Administration (Intravenous, Subcutaneous), End User - Global Forecast to 2029

FREE BROCHURE FREE SAMPLE REPORT
Report Code: PH 3926 Jul, 2024, by marketsandmarkets.com

Immunotherapy Drugs Market Size, Share & Trends

The size of global immunotherapy drugs market in terms of revenue was estimated to be worth $285.3 billion in 2024 and is poised to reach $580.6 billion by 2029, growing at a CAGR of 15.3% from 2024 to 2029. The comprehensive research encompasses an exhaustive examination of industry trends, meticulous pricing analysis, patent scrutiny, insights derived from conferences and webinars, identification of key stakeholders, and a nuanced understanding of market purchasing dynamics.

This growth is driven by technological advancements in antibody engineering, increasing demand for antibody therapies in clinical cancer treatment, and a growing preference for personalized medicines and targeted therapies. Immunotherapy drugs are designed to enhance the immune response or modulate the immune system's regulatory mechanisms, thereby enabling the body to effectively target and eliminate disease-causing agents or cells. However, the market faces challenges such as the complexities involved in developing antibody therapeutics. Key drivers of the market growth include technological advancements in antibody engineering, the rising demand for antibody therapies in clinical cancer treatment, and the increasing need for personalized medicines and targeted therapies.

Immunotherapy Drugs Market Trends

Immunotherapy Drugs Market

To know about the assumptions considered for the study, Request for Free Sample Report

Immunotherapy Drugs Market

Immunotherapy Drugs Market Dynamics

DRIVER: Technological advancements in antibody engineering

Advancements in antibody engineering are significantly driving the growth of the immunotherapy drugs market by leveraging molecular biology techniques to enhance antibodies for therapeutic and diagnostic purposes, the development of highly targeted and effective treatments is facilitated. Technologies such as recombinant DNA enable the customization of antibodies for specific therapeutic applications, increasing their clinical efficacy. Platforms like Wacker's ESETEC and Ligand Pharmaceuticals' Pelican Expression Technology optimize the production and secretion of antibody fragments, further propelling market growth. These innovations are crucial in meeting the rising demand for personalized medicines and targeted therapies, thereby expanding the market for immunotherapy drugs.

RESTRAINT: Stringent regulatory approval process for immunotherapy drugs

Developing and commercializing immunotherapy drugs faces rigorous evaluation and compliance with complex regulatory frameworks. The US FDA and European Medicines Agency (EMA) impose stringent guidelines, resulting in prolonged approval timelines and significant financial investments. Smaller companies face challenges due to these exhaustive requirements. Guidelines from the EMA and WHO cover development, production, and evaluation of antibody therapeutics. Regulatory rejections, such as those experienced by Y-mAbs Therapeutics and Eli Lilly, highlight the challenges. Market players must diligently adhere to these regulations to navigate the approval process and succeed in the competitive landscape of antibody therapeutics.

OPPORTUNITY: Increasing collaborations among pharmaceutical companies, CROs, CDMOs, and academic institutions

A collaborative approach fosters a synergistic environment, driving advancements in R&D and commercialization of Immunotherapy Drugs. Academic institutions contribute cutting-edge research, while pharmaceutical companies offer formulation expertise and market knowledge. CROs ensure robust scientific validation and regulatory compliance. Notable collaborations include AstraZeneca and the University Health Network's phase II study on AZD2936 for LA-HNSCC, and Salipro Biotech's multi-target antibody research agreement with Icosagen. This collaborative strategy promotes innovation, accelerates drug development, reduces costs, and enhances global market penetration, positioning antibody fragment-based therapies for substantial market growth and clinical impact.

CHALLENGE: Complexities in development of antibody therapeutics

The production of antibody therapeutics is intricate and time-consuming, involving cell line development, bioreactor cultivation, and purification, leading to high production costs and affecting market competitiveness. Compliance with stringent regulatory guidelines further increases costs and causes delays. Manufacturing involves complex operations and rigorous quality assurance, making antibody therapies more expensive than small-molecule medicines. Limited specialized manufacturing facilities force companies to outsource production, adding to costs and posing a challenge to market growth. The use of expression systems for antibody fragments through recombinant DNA technology is critical but resource-intensive.

IMMUNOTHERAPY DRUGS MARKET ECOSYSTEM

Based on the current scenario of commercializing immunotherapy drugs, the immunotherapy drugs value chain includes four integral steps. These are research & development; Manufacturing,Packaging, Distribution, Marketing Sales and After Sales. Within this value chain, Formulation Development, Extraction, Synthesis, Packaging and Sterlization are critical steps in commercializing immunotherapy drugs. The supply chain for immunotherapy drugs spans the entire process of sourcing materials to distribute the final product to healthcare providers (hospitals, clinics/physician settings) or patients. Based on the complexity of immunotherapy drugs manufacturing and the need for stringent quality control, establishing a robust supply chain is essential for ensuring the safety, efficacy, and scalability of immunotherapy drugs.

Ecosystem analysis: Immunotherapy Drugs Market

Immunotherapy Drugs Market Ecosystem

Source: Annual Reports, SEC Filings, Investor Presentations, Expert Interviews, and MarketsandMarkets Analysis

The Antibody drugs segment maintains major market share of the immunotherapy drugs industry in the forecast period.

Based on type, the immunotherapy drugs market is divided into antibody drugs, inhibitor drugs, interferons & interleukins, cancer vaccines, and other immunotherapy drugs, which include oncolytic virus therapy and t-cell therapy. Antibody drugs hold the major market share in 2023. Rising cancer rates along with the growing adoption of biological therapies, increased spending on R&D by both governments and Immunotherapy Drug Companies coupled with favorable government policies are driving this market.

The Cancer segment is anticipated to dominate immunotherapy drugs industry through 2023-2029.

Based on applications, the immunotherapy drugs market is divided into cancer, autoimmune & inflammatory diseases, hematology, osteology, neurology, and other applications, including ophthalmology, dermatology, and cardiovascular diseases. Cancer commanded the largest market share in 2023 due to the projected growth in burden of cancer cases throughout the world along with rising product approvals for cancer application, and increased R&D Spending.

The Intravenous Route segment of the immunotherapy drugs industry is anticipated to grow at the fastest pace throughout the forecast period.

Based on the route of administration, the immunotherapy drugs market is broadly segmented into intravenous, subcutaneous, and other routes of administration (intravitreal and intramuscular). In 2023, the intravenous route of administration segment accounted for the largest share of the immunotherapy drugs market. This segment is also expected to grow at the highest CAGR during the forecast period. The large share and high growth rate are attributed to the growing preference for intravenous routes owing to its direct delivery into the bloodstream, ensuring rapid and consistent therapeutic effects for several conditions, including cancer and autoimmune diseases.

Hospitals segment of the immunotherapy drugs industry generated the highest revenue in 2024 in the market.

Based on end users, the immunotherapy drugs market is broadly segmented into hospitals, long-term care facilities, and other end users (specialty care centers). In 2023, the hospitals segment commanded the largest share of the immunotherapy drugs market. Hospitals extensively use mAbs for their targeted therapy, rapid diagnostic applications, and efficacy in treating several disease indications, including cancer, autoimmune disorders, and infectious diseases.

The North America immunotherapy drugs industry is expected to dominate the market.

The immunotherapy drugs market has been segmented into six major regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. In 2023, North America accounted for the largest share of the global immunotherapy drugs market. The growth in the North American market can be attributed to rising immunotherapy research, the expansion of the healthcare sector, growing cancer prevalence, and the increasing approval and adoption of immunotherapy drugs for treating cancer and other chronic diseases.

Immunotherapy Drugs Market by Region

To know about the assumptions considered for the study, download the pdf brochure

The players mapped in the report include Merck & Co., Inc. (US), Johnson & Johnson Services, Inc. (US), F. Hoffman-La Roche Ltd. (Switzerland), Pfizer Inc. (US), AstraZeneca (UK), Novartis AG (Switzerland), Amgen Inc. (US), Gilead Sciences, Inc. (UK), Bristol-Myers Squibb Company (US), Eli Lilly and Company (US), Sanofi (France), Takeda Pharmaceutical Company Limited (Japan), Teva Pharmaceutical Industries Ltd (Israel), GSK PLC (US), and Abbvie Inc. (US).

Scope of the Immunotherapy Drugs Industry:

Report Metric

Details

Market Revenue in 2024

$285.3 billion

Projected Revenue by 2029

$580.6 billion

Revenue Rate

Poised to Grow at a CAGR of 15.3%

Market Driver

Technological advancements in antibody engineering

Market Opportunity

Increasing collaborations among pharmaceutical companies, CROs, CDMOs, and academic institutions

This research report categorizes the immunotherapy drugs market to forecast revenue and analyze trends in each of the following submarkets:

By Type
  • Antibody Drugs
  • Inhibitor Drugs
  • Interferons and Interleukins
  • Cancer Vaccines
  • Other Types
By Application
  • Cancer
  • Autoimmune and Inflammatory Diseases
  • Hematology
  • Osteology
  • Neurology
  • Other Applications
y Route of Administration
  • Intravenous
  • Subcutaneous
  • Other Routes of Administration
By End User
  • Hospitals
  • Long-Term Care Facilities
  • Other End Users
By Region
  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • South Korea
    • Australia
    • India
    • Japan
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East
    • GCC
      • Saudi Arabia (KSA)
      • United Arab Emirates (UAE)
      • Rest of GCC
    • Rest of Middle East
  • Africa

Recent Developments of Immunotherapy Drugs Industry:

  • In May 2024, Merck acquired EyeBio (UK), a privately held ophthalmology-focused biotechnology company. Merck gained rights to EyeBio’s pipeline candidate—Restoret (EYE103) through this acquisition. This is an investigational tri-specific antibody that acts as an agonist of the wingless-related integration site (WNT) signaling pathway.
  • In December 2023, F. Hoffman-La Roche acquired Telavant Holdings, Inc. (owned by Roivant Sciences Ltd. and Pfizer Inc.) to develop advanced therapies targeted toward gastrointestinal health.
  • In May 2023, Janssen Global Services, LLC (a subsidiary company of J&J) collaborated with Cellular Biomedicine Group Inc. (CBMG) to develop and commercialize advanced chimeric antigen receptor (CAR) T-cell therapies to treat B-cell malignancies.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 43)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS & EXCLUSIONS
                    TABLE 1 IMMUNOTHERAPY DRUGS MARKET: INCLUSIONS & EXCLUSIONS
    1.3 STUDY SCOPE 
           1.3.1 SEGMENTS COVERED
                    FIGURE 1 IMMUNOTHERAPY DRUGS MARKET: SEGMENTS COVERED
           1.3.2 REGIONS COVERED
                    FIGURE 2 IMMUNOTHERAPY DRUGS MARKET: REGIONS COVERED
           1.3.3 YEARS CONSIDERED
                    FIGURE 3 IMMUNOTHERAPY DRUGS MARKET: YEARS CONSIDERED
           1.3.4 CURRENCY CONSIDERED
           1.3.5 UNITS CONSIDERED
    1.4 STAKEHOLDERS 
    1.5 SUMMARY OF CHANGES 
           1.5.1 RECESSION IMPACT
 
2 RESEARCH METHODOLOGY (Page No. - 48)
    2.1 RESEARCH DATA 
          FIGURE 4 IMMUNOTHERAPY DRUGS MARKET: RESEARCH DESIGN
           2.1.1 SECONDARY DATA
                    2.1.1.1 Objectives of secondary research
           2.1.2 PRIMARY DATA
                    2.1.2.1 Breakdown of primaries
                                FIGURE 5 IMMUNOTHERAPY DRUGS MARKET: BREAKDOWN OF PRIMARIES
    2.2 MARKET ESTIMATION METHODOLOGY 
          FIGURE 6 IMMUNOTHERAPY DRUGS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2023
           2.2.1 COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH)
                    FIGURE 7 MARKET SIZE ESTIMATION: COMPANY REVENUE ANALYSIS-BASED ESTIMATION, 2023
           2.2.2 INSIGHTS FROM PRIMARY EXPERTS
                    FIGURE 8 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
    2.3 MARKET GROWTH RATE PROJECTIONS 
          FIGURE 9 IMMUNOTHERAPY DRUGS MARKET: CAGR PROJECTIONS
          FIGURE 10 IMMUNOTHERAPY DRUGS MARKET: ANALYSIS OF DEMAND-SIDE DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    2.4 DATA TRIANGULATION 
          FIGURE 11 DATA TRIANGULATION METHODOLOGY
    2.5 STUDY ASSUMPTIONS 
    2.6 RISK ANALYSIS 
          TABLE 2 IMMUNOTHERAPY DRUGS MARKET: RISK ANALYSIS
    2.7 IMPACT OF ECONOMIC RECESSION ON IMMUNOTHERAPY DRUGS MARKET 
          TABLE 3 GLOBAL INFLATION RATE PROJECTIONS, 2021–2028 (% GROWTH)
 
3 EXECUTIVE SUMMARY (Page No. - 58)
    FIGURE 12 IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2024 VS. 2029 (USD BILLION)
    FIGURE 13 IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2024 VS. 2029 (USD BILLION)
    FIGURE 14 IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2024 VS. 2029 (USD BILLION)
    FIGURE 15 IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2024 VS. 2029 (USD BILLION)
    FIGURE 16 IMMUNOTHERAPY DRUGS MARKET: REGIONAL SNAPSHOT
 
4 PREMIUM INSIGHTS (Page No. - 62)
    4.1 IMMUNOTHERAPY DRUGS MARKET OVERVIEW 
          FIGURE 17 TECHNOLOGICAL ADVANCEMENTS IN ANTIBODY ENGINEERING TO DRIVE MARKET
    4.2 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE AND COUNTRY (2023) 
          FIGURE 18 US AND ANTIBODY DRUGS SEGMENT COMMANDED LARGEST MARKET SHARE IN 2023
    4.3 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2024 VS. 2029 (USD BILLION) 
          FIGURE 19 ANTIBODY DRUGS TO DOMINATE NORTH AMERICAN MARKET DURING STUDY PERIOD
 
5 MARKET OVERVIEW (Page No. - 65)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 20 IMMUNOTHERAPY DRUGS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
          TABLE 4 IMMUNOTHERAPY DRUGS MARKET: IMPACT ANALYSIS
           5.2.1 DRIVERS
                    5.2.1.1 Technological advancements in antibody engineering
                    5.2.1.2 Increasing demand for antibody therapeutics in clinical cancer treatment
                                TABLE 5 NUMBER OF APPROVED PRODUCTS BY US FDA/EMA, 2015–2023
                    5.2.1.3 Growing demand for personalized medicines and targeted therapies
           5.2.2 RESTRAINTS
                    5.2.2.1 Stringent regulatory approval process for immunotherapy drugs
                    5.2.2.2 High cost of monoclonal antibody therapeutics
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Rising number of approvals for CAR T-cell therapies
                                TABLE 6 APPROVED AUTOLOGOUS CAR T-CELL THERAPIES
                    5.2.3.2 Increasing collaborations among pharmaceutical companies, CROs, CDMOs, and academic institutes
           5.2.4 CHALLENGES
                    5.2.4.1 Complexities in development of antibody therapeutics
    5.3 PORTER’S FIVE FORCES ANALYSIS 
          FIGURE 21 IMMUNOTHERAPY DRUGS MARKET: PORTER’S FIVE FORCES ANALYSIS
          TABLE 7 IMMUNOTHERAPY DRUGS MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.3.1 THREAT OF NEW ENTRANTS
           5.3.2 THREAT OF SUBSTITUTES
           5.3.3 BARGAINING POWER OF SUPPLIERS
           5.3.4 BARGAINING POWER OF BUYERS
           5.3.5 INTENSITY OF COMPETITIVE RIVALRY
    5.4 KEY STAKEHOLDERS & BUYING CRITERIA 
           5.4.1 KEY STAKEHOLDERS IN BUYING PROCESS
                    FIGURE 22 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS OF IMMUNOTHERAPY DRUGS
           5.4.2 KEY BUYING CRITERIA
                    FIGURE 23 KEY BUYING CRITERIA FOR HOSPITALS AND LONG-TERM CARE FACILITIES
    5.5 VALUE CHAIN ANALYSIS 
          FIGURE 24 IMMUNOTHERAPY DRUGS MARKET: VALUE CHAIN ANALYSIS
    5.6 SUPPLY CHAIN ANALYSIS 
          FIGURE 25 IMMUNOTHERAPY DRUGS MARKET: SUPPLY CHAIN ANALYSIS
    5.7 PRICING ANALYSIS 
           5.7.1 AVERAGE SELLING PRICE OF IMMUNOTHERAPY DRUGS, BY KEY PLAYER
                    FIGURE 26 AVERAGE SELLING PRICE TREND OF IMMUNOTHERAPY DRUGS, BY KEY PLAYER
           5.7.2 AVERAGE COST RANGE OF IMMUNOTHERAPY DRUGS, BY KEY PLAYER, 2021–2023
                    TABLE 8 AVERAGE COST RANGE OF IMMUNOTHERAPY DRUGS, BY KEY PLAYER, 2021–2023
           5.7.3 INDICATIVE PRICE OF ANTIBODY THERAPEUTICS, BY ROUTE OF ADMINISTRATION
                    TABLE 9 INDICATIVE PRICE OF ANTIBODY THERAPEUTICS, BY ROUTE OF ADMINISTRATION
           5.7.4 INDICATIVE PRICE OF IMMUNOTHERAPY DRUGS, BY REGION
                    TABLE 10 INDICATIVE PRICE OF IMMUNOTHERAPY DRUGS, BY REGION
    5.8 ECOSYSTEM ANALYSIS 
          FIGURE 27 IMMUNOTHERAPY DRUGS MARKET: ECOSYSTEM MAP
           5.8.1 ROLE IN ECOSYSTEM (SUPPLY AND DEMAND SIDES)
                    TABLE 11 IMMUNOTHERAPY DRUGS MARKET: ROLE IN ECOSYSTEM (SUPPLY AND DEMAND SIDES)
    5.9 PATENT ANALYSIS 
          FIGURE 28 PATENT APPLICATIONS FOR IMMUNOTHERAPY DRUGS (JANUARY 2012–DECEMBER 2023)
    5.10 TECHNOLOGY ANALYSIS 
           5.10.1 KEY TECHNOLOGIES
                    5.10.1.1 Gene editing
                    5.10.1.2 High-throughput screening
                    5.10.1.3 Next-generation sequencing
           5.10.2 COMPLEMENTARY TECHNOLOGIES
                    5.10.2.1 Nanotechnology
                    5.10.2.2 Artificial intelligence
    5.11 INVESTMENT & FUNDING SCENARIO 
           5.11.1 MAJOR INVESTMENTS AND FUNDING
                     TABLE 12 IMMUNOTHERAPY DRUGS MARKET: MAJOR INVESTMENTS AND FUNDING, JANUARY 2021–MAY 2024
           5.11.2 OTHER INVESTMENTS AND FUNDING
    5.12 KEY CONFERENCES & EVENTS, 2024–2025 
           TABLE 13 IMMUNOTHERAPY DRUGS MARKET: LIST OF KEY CONFERENCES & EVENTS, JANUARY 2024–DECEMBER 2025
    5.13 CASE STUDY ANALYSIS 
           5.13.1 CASE STUDY 1: EFFICACY OF KEYTRUDA IN CANCER TREATMENT
           5.13.2 CASE STUDY 2: EFFECTIVE USE OF LYNPARZA IN PROSTATE CANCER TREATMENT
           5.13.3 CASE STUDY 3: CLINICAL TRIALS OF ORPATHYS (SAVOLITINIB)
    5.14 REGULATORY LANDSCAPE 
           5.14.1 REGULATORY ANALYSIS
                    5.14.1.1 North America
                               5.14.1.1.1 US
                               5.14.1.1.2 Canada
                    5.14.1.2 Europe
                               5.14.1.2.1 Germany
                               5.14.1.2.2 UK
                               5.14.1.2.3 Rest of Europe
                    5.14.1.3 Asia Pacific
                               5.14.1.3.1 China
                               5.14.1.3.2 Japan
                               5.14.1.3.3 South Korea
                               5.14.1.3.4 Australia
           5.14.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    5.14.2.1 North America
                                 TABLE 14 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    5.14.2.2 Europe
                                 TABLE 15 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    5.14.2.3 Asia Pacific
                                 TABLE 16 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    5.14.2.4 Latin America
                                 TABLE 17 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    5.14.2.5 Middle East & Africa
                                 TABLE 18 MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
6 IMMUNOTHERAPY DRUGS MARKET, BY TYPE (Page No. - 107)
    6.1 INTRODUCTION 
          TABLE 19 IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)
          TABLE 20 IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (UNITS)
    6.2 ANTIBODY DRUGS 
           6.2.1 ROBUST CLINICAL PIPELINE OF ANTIBODY THERAPEUTICS TO SUPPORT MARKET GROWTH
                    TABLE 21 ANTIBODY DRUGS MARKET, BY REGION, 2022–2029 (USD BILLION)
                    TABLE 22 NORTH AMERICA: ANTIBODY DRUGS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
                    TABLE 23 EUROPE: ANTIBODY DRUGS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
                    TABLE 24 ASIA PACIFIC: ANTIBODY DRUGS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
                    TABLE 25 LATIN AMERICA: ANTIBODY DRUGS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
                    TABLE 26 MIDDLE EAST: ANTIBODY DRUGS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
                    TABLE 27 GCC COUNTRIES: ANTIBODY DRUGS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
    6.3 INHIBITOR DRUGS 
           6.3.1 INCREASED FOCUS ON DEVELOPMENT OF TARGET MEDICINES AND COMBINATION THERAPIES TO FUEL MARKET GROWTH
                    TABLE 28 INHIBITOR DRUGS MARKET, 2022–2029 (USD BILLION)
                    TABLE 29 NORTH AMERICA: INHIBITOR DRUGS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
                    TABLE 30 EUROPE: INHIBITOR DRUGS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
                    TABLE 31 ASIA PACIFIC: INHIBITOR DRUGS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
                    TABLE 32 LATIN AMERICA: INHIBITOR DRUGS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
                    TABLE 33 MIDDLE EAST: INHIBITOR DRUGS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
                    TABLE 34 GCC COUNTRIES: INHIBITOR DRUGS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
    6.4 INTERFERONS & INTERLEUKINS 
           6.4.1 INCREASED FOCUS ON R&D AND DEVELOPMENT OF NEW IMMUNOTHERAPY DRUGS TO AUGMENT MARKET GROWTH
                    TABLE 35 INTERFERONS & INTERLEUKINS MARKET, BY REGION, 2022–2029 (USD BILLION)
                    TABLE 36 NORTH AMERICA: INTERFERONS & INTERLEUKINS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
                    TABLE 37 EUROPE: INTERFERONS & INTERLEUKINS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
                    TABLE 38 ASIA PACIFIC: INTERFERONS & INTERLEUKINS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
                    TABLE 39 LATIN AMERICA: INTERFERONS & INTERLEUKINS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
                    TABLE 40 MIDDLE EAST: INTERFERONS & INTERLEUKINS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
                    TABLE 41 GCC COUNTRIES: INTERFERONS & INTERLEUKINS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
    6.5 CANCER VACCINES 
           6.5.1 RISING FOCUS ON RESEARCH ACTIVITIES AND CLINICAL TRIALS TO SPUR MARKET GROWTH
                    TABLE 42 CANCER VACCINES MARKET, BY REGION, 2022–2029 (USD BILLION)
                    TABLE 43 NORTH AMERICA: CANCER VACCINES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
                    TABLE 44 EUROPE: CANCER VACCINES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
                    TABLE 45 ASIA PACIFIC: CANCER VACCINES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
                    TABLE 46 LATIN AMERICA: CANCER VACCINES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
                    TABLE 47 MIDDLE EAST: CANCER VACCINES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
                    TABLE 48 GCC COUNTRIES: CANCER VACCINES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
    6.6 OTHER IMMUNOTHERAPY DRUGS 
          TABLE 49 OTHER IMMUNOTHERAPY DRUGS MARKET, BY REGION, 2022–2029 (USD BILLION)
          TABLE 50 NORTH AMERICA: OTHER IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
          TABLE 51 EUROPE: OTHER IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
          TABLE 52 ASIA PACIFIC: OTHER IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
          TABLE 53 LATIN AMERICA: OTHER IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
          TABLE 54 MIDDLE EAST: OTHER IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
          TABLE 55 GCC COUNTRIES: OTHER IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
 
7 IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION (Page No. - 126)
    7.1 INTRODUCTION 
          TABLE 56 IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
    7.2 CANCER 
           7.2.1 LARGE R&D SPENDING AND HIGH GOVERNMENT INVESTMENTS TO DRIVE MARKET
                    TABLE 57 IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY REGION, 2022–2029 (USD BILLION)
                    TABLE 58 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD BILLION)
                    TABLE 59 EUROPE: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD BILLION)
                    TABLE 60 ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD BILLION)
                    TABLE 61 LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD BILLION)
                    TABLE 62 MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY REGION, 2022–2029 (USD BILLION)
                    TABLE 63 GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD BILLION)
    7.3 AUTOIMMUNE & INFLAMMATORY DISEASES 
           7.3.1 ADVANCEMENTS IN MOLECULAR ENGINEERING AND INTRODUCTION OF BIOLOGICAL DRUGS TO PROPEL MARKET GROWTH
                    TABLE 64 IMMUNOTHERAPY DRUGS MARKET FOR AUTOIMMUNE & INFLAMMATORY DISEASES, BY REGION, 2022–2029 (USD BILLION)
                    TABLE 65 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR AUTOIMMUNE & INFLAMMATORY DISEASES, BY COUNTRY, 2022–2029 (USD BILLION)
                    TABLE 66 EUROPE: IMMUNOTHERAPY DRUGS MARKET FOR AUTOIMMUNE & INFLAMMATORY DISEASES, BY COUNTRY, 2022–2029 (USD BILLION)
                    TABLE 67 ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET FOR AUTOIMMUNE & INFLAMMATORY DISEASES, BY COUNTRY, 2022–2029 (USD BILLION)
                    TABLE 68 LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR AUTOIMMUNE & INFLAMMATORY DISEASES, BY COUNTRY, 2022–2029 (USD BILLION)
                    TABLE 69 MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET FOR AUTOIMMUNE & INFLAMMATORY DISEASES, BY REGION, 2022–2029 (USD BILLION)
                    TABLE 70 GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET FOR AUTOIMMUNE & INFLAMMATORY DISEASES, BY COUNTRY, 2022–2029 (USD BILLION)
    7.4 HEMATOLOGY 
           7.4.1 INCREASED R&D IN CELL-BASED THERAPIES, MONOCLONAL ANTIBODIES, AND IMMUNE CHECKPOINT INHIBITORS TO AID MARKET GROWTH
                    TABLE 71 IMMUNOTHERAPY DRUGS MARKET FOR HEMATOLOGY, BY REGION, 2022–2029 (USD BILLION)
                    TABLE 72 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2029 (USD BILLION)
                    TABLE 73 EUROPE: IMMUNOTHERAPY DRUGS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2029 (USD BILLION)
                    TABLE 74 ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2029 (USD BILLION)
                    TABLE 75 LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2029 (USD BILLION)
                    TABLE 76 MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET FOR HEMATOLOGY, BY REGION, 2022–2029 (USD BILLION)
                    TABLE 77 GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2029 (USD BILLION)
    7.5 OSTEOLOGY 
           7.5.1 GROWING INCIDENCE OF OSTEOPOROSIS-RELATED FRACTURES TO DRIVE MARKET
                    TABLE 78 IMMUNOTHERAPY DRUGS MARKET FOR OSTEOLOGY, BY REGION, 2022–2029 (USD BILLION)
                    TABLE 79 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR OSTEOLOGY, BY COUNTRY, 2022–2029 (USD BILLION)
                    TABLE 80 EUROPE: IMMUNOTHERAPY DRUGS MARKET FOR OSTEOLOGY, BY COUNTRY, 2022–2029 (USD BILLION)
                    TABLE 81 ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET FOR OSTEOLOGY, BY COUNTRY, 2022–2029 (USD BILLION)
                    TABLE 82 LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR OSTEOLOGY, BY COUNTRY, 2022–2029 (USD BILLION)
                    TABLE 83 MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET FOR OSTEOLOGY, BY REGION, 2022–2029 (USD BILLION)
                    TABLE 84 GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET FOR OSTEOLOGY, BY COUNTRY, 2022–2029 (USD BILLION)
    7.6 NEUROLOGY 
           7.6.1 ADVANCEMENTS IN NEUROLOGICAL DRUG DEVELOPMENT TO BOOST MARKET GROWTH
                    TABLE 85 IMMUNOTHERAPY DRUGS MARKET FOR NEUROLOGY, BY REGION, 2022–2029 (USD BILLION)
                    TABLE 86 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR NEUROLOGY, BY COUNTRY, 2022–2029 (USD BILLION)
                    TABLE 87 EUROPE: IMMUNOTHERAPY DRUGS MARKET FOR NEUROLOGY, BY COUNTRY, 2022–2029 (USD BILLION)
                    TABLE 88 ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET FOR NEUROLOGY, BY COUNTRY, 2022–2029 (USD BILLION)
                    TABLE 89 LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR NEUROLOGY, BY COUNTRY, 2022–2029 (USD BILLION)
                    TABLE 90 MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET FOR NEUROLOGY, BY REGION, 2022–2029 (USD BILLION)
                    TABLE 91 GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET FOR NEUROLOGY, BY COUNTRY, 2022–2029 (USD BILLION)
    7.7 OTHER APPLICATIONS 
          TABLE 92 IMMUNOTHERAPY DRUGS MARKET FOR OTHER APPLICATIONS, BY REGION, 2022–2029 (USD BILLION)
          TABLE 93 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD BILLION)
          TABLE 94 EUROPE: IMMUNOTHERAPY DRUGS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD BILLION)
          TABLE 95 ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD BILLION)
          TABLE 96 LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD BILLION)
          TABLE 97 MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET FOR OTHER APPLICATIONS, BY REGION, 2022–2029 (USD BILLION)
          TABLE 98 GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD BILLION)
 
8 IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION (Page No. - 148)
    8.1 INTRODUCTION 
          TABLE 99 IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
    8.2 INTRAVENOUS ROUTE OF ADMINISTRATION 
           8.2.1 DIRECT DELIVERY OF THERAPEUTIC DOSAGE TO PROPEL MARKET GROWTH
                    TABLE 100 IMMUNOTHERAPY DRUGS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY REGION, 2022–2029 (USD BILLION)
                    TABLE 101 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD BILLION)
                    TABLE 102 EUROPE: IMMUNOTHERAPY DRUGS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD BILLION)
                    TABLE 103 ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD BILLION)
                    TABLE 104 LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD BILLION)
                    TABLE 105 MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY REGION, 2022–2029 (USD BILLION)
                    TABLE 106 GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD BILLION)
    8.3 SUBCUTANEOUS ROUTE OF ADMINISTRATION 
           8.3.1 ENHANCED PATIENT ADHERENCE AND LOW HEALTHCARE COSTS TO AID MARKET GROWTH
                    TABLE 107 IMMUNOTHERAPY DRUGS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY REGION, 2022–2029 (USD BILLION)
                    TABLE 108 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD BILLION)
                    TABLE 109 EUROPE: IMMUNOTHERAPY DRUGS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD BILLION)
                    TABLE 110 ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD BILLION)
                    TABLE 111 LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD BILLION)
                    TABLE 112 MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY REGION, 2022–2029 USD BILLION)
                    TABLE 113 GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD BILLION)
    8.4 OTHER ROUTES OF ADMINISTRATION 
          TABLE 114 IMMUNOTHERAPY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2022–2029 (USD BILLION)
          TABLE 115 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD BILLION)
          TABLE 116 EUROPE: IMMUNOTHERAPY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD BILLION)
          TABLE 117 ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD BILLION)
          TABLE 118 LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD BILLION)
          TABLE 119 MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2022–2029 (USD BILLION)
          TABLE 120 GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD BILLION)
 
9 IMMUNOTHERAPY DRUGS MARKET, BY END USER (Page No. - 160)
    9.1 INTRODUCTION 
          TABLE 121 IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2022–2029 (USD BILLION)
    9.2 HOSPITALS 
           9.2.1 AVAILABILITY OF ADVANCED HEALTHCARE INFRASTRUCTURE AND EXPERTISE TO AUGMENT MARKET GROWTH
                    TABLE 122 IMMUNOTHERAPY DRUGS MARKET FOR HOSPITALS, BY REGION, 2022–2029 (USD BILLION)
                    TABLE 123 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD BILLION)
                    TABLE 124 EUROPE: IMMUNOTHERAPY DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD BILLION)
                    TABLE 125 ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD BILLION)
                    TABLE 126 LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD BILLION)
                    TABLE 127 MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET FOR HOSPITALS, BY REGION, 2022–2029 (USD BILLION)
                    TABLE 128 GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD BILLION)
    9.3 LONG-TERM CARE FACILITIES 
           9.3.1 SPECIALIZED CARE AND CONTINUOUS MONITORING FOR PATIENTS WITH CHRONIC HEALTH CONDITIONS TO DRIVE MARKET
                    TABLE 129 IMMUNOTHERAPY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022–2029 (USD BILLION)
                    TABLE 130 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD BILLION)
                    TABLE 131 EUROPE: IMMUNOTHERAPY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD BILLION)
                    TABLE 132 ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD BILLION)
                    TABLE 133 LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD BILLION)
                    TABLE 134 MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022–2029 (USD BILLION)
                    TABLE 135 GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD BILLION)
    9.4 OTHER END USERS 
          TABLE 136 IMMUNOTHERAPY DRUGS MARKET FOR OTHER END USERS, BY REGION, 2022–2029 (USD BILLION)
          TABLE 137 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD BILLION)
          TABLE 138 EUROPE: IMMUNOTHERAPY DRUGS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD BILLION)
          TABLE 139 ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD BILLION)
          TABLE 140 LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD BILLION)
          TABLE 141 MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET FOR OTHER END USERS, BY REGION, 2022–2029 (USD BILLION)
          TABLE 142 GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD BILLION)
 
10 IMMUNOTHERAPY DRUGS MARKET, BY REGION (Page No. - 172)
     10.1 INTRODUCTION 
             TABLE 143 IMMUNOTHERAPY DRUGS MARKET, BY REGION, 2022–2029 (USD BILLION)
     10.2 NORTH AMERICA 
             FIGURE 29 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET SNAPSHOT
             TABLE 144 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
             TABLE 145 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)
             TABLE 146 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
             TABLE 147 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
             TABLE 148 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2022–2029 (USD BILLION)
             10.2.1 NORTH AMERICA: RECESSION IMPACT
             10.2.2 US
                        10.2.2.1 US to dominate North American immunotherapy drugs market during forecast period
                                      TABLE 149 US: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)
                                      TABLE 150 US: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
                                      TABLE 151 US: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
                                      TABLE 152 US: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2022–2029 (USD BILLION)
             10.2.3 CANADA
                        10.2.3.1 Rising government initiatives for research on regenerative medicine to drive market
                                      TABLE 153 CANADA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)
                                      TABLE 154 CANADA: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
                                      TABLE 155 CANADA: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
                                      TABLE 156 CANADA: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2022–2029 (USD BILLION)
     10.3 EUROPE 
             TABLE 157 EUROPE: IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
             TABLE 158 EUROPE: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)
             TABLE 159 EUROPE: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
             TABLE 160 EUROPE: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
             TABLE 161 EUROPE: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2022–2029 (USD BILLION)
             10.3.1 EUROPE: RECESSION IMPACT
             10.3.2 GERMANY
                        10.3.2.1 Increasing investments in healthcare research to fuel market growth
                                      TABLE 162 GERMANY: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)
                                      TABLE 163 GERMANY: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
                                      TABLE 164 GERMANY: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
                                      TABLE 165 GERMANY: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2022–2029 (USD BILLION)
             10.3.3 UK
                        10.3.3.1 Favorable government initiatives and high R&D investments to propel market growth
                                      TABLE 166 UK: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)
                                      TABLE 167 UK: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
                                      TABLE 168 UK: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
                                      TABLE 169 UK: IMMUNOTHERAPY DRUGS THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD BILLION)
             10.3.4 FRANCE
                        10.3.4.1 Increasing adoption of immunotherapy drugs and growing focus on healthcare R&D to augment market growth
                                      TABLE 170 FRANCE: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)
                                      TABLE 171 FRANCE: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
                                      TABLE 172 FRANCE: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
                                      TABLE 173 FRANCE: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2022–2029 (USD BILLION)
             10.3.5 ITALY
                        10.3.5.1 Strong focus on clinical research and stringent government regulations to propel market growth
                                      TABLE 174 ITALY: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)
                                      TABLE 175 ITALY: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
                                      TABLE 176 ITALY: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
                                      TABLE 177 ITALY: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2022–2029 (USD BILLION)
             10.3.6 SPAIN
                        10.3.6.1 Favorable government initiatives to spur market growth
                                      TABLE 178 SPAIN: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)
                                      TABLE 179 SPAIN: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
                                      TABLE 180 SPAIN: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
                                      TABLE 181 SPAIN: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2022–2029 (USD BILLION)
             10.3.7 REST OF EUROPE
                        TABLE 182 REST OF EUROPE: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)
                        TABLE 183 REST OF EUROPE: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
                        TABLE 184 REST OF EUROPE: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
                        TABLE 185 REST OF EUROPE: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2022–2029 (USD BILLION)
     10.4 ASIA PACIFIC 
             FIGURE 30 ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET SNAPSHOT
             TABLE 186 ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
             TABLE 187 ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)
             TABLE 188 ASIA PACIFIC: IMMUNOTHERAPY DRUGS, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
             TABLE 189 ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
             TABLE 190 ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2022–2029 (USD BILLION)
             10.4.1 ASIA PACIFIC: RECESSION IMPACT
             10.4.2 CHINA
                        10.4.2.1 Less-stringent regulatory framework and high incidence of cancer to drive market
                                      TABLE 191 CHINA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)
                                      TABLE 192 CHINA: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
                                      TABLE 193 CHINA: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
                                      TABLE 194 CHINA: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2022–2029 (USD BILLION)
             10.4.3 JAPAN
                        10.4.3.1 Rising geriatric population and increasing government support to augment market growth
                                      TABLE 195 JAPAN: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)
                                      TABLE 196 JAPAN: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
                                      TABLE 197 JAPAN: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
                                      TABLE 198 JAPAN: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2022–2029 (USD BILLION)
             10.4.4 INDIA
                        10.4.4.1 Increasing prevalence of cancer and rising government healthcare investments to aid market growth
                                      TABLE 199 INDIA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)
                                      TABLE 200 INDIA: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
                                      TABLE 201 INDIA: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
                                      TABLE 202 INDIA: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2022–2029 (USD BILLION)
             10.4.5 SOUTH KOREA
                        10.4.5.1 Strong biopharmaceutical sector and favorable government initiatives to support market growth
                                      TABLE 203 SOUTH KOREA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)
                                      TABLE 204 SOUTH KOREA: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
                                      TABLE 205 SOUTH KOREA: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
                                      TABLE 206 SOUTH KOREA: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2022–2029 (USD BILLION)
             10.4.6 AUSTRALIA
                        10.4.6.1 High prevalence of cancer and increased expenditure on health services to propel market growth
                                      TABLE 207 AUSTRALIA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)
                                      TABLE 208 AUSTRALIA: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
                                      TABLE 209 AUSTRALIA: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
                                      TABLE 210 AUSTRALIA: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2022–2029 (USD BILLION)
             10.4.7 REST OF ASIA PACIFIC
                        TABLE 211 REST OF ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)
                        TABLE 212 REST OF ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
                        TABLE 213 REST OF ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
                        TABLE 214 REST OF ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2022–2029 (USD BILLION)
     10.5 LATIN AMERICA 
             TABLE 215 LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
             TABLE 216 LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)
             TABLE 217 LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
             TABLE 218 LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
             TABLE 219 LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2022–2029 (USD BILLION)
             10.5.1 LATIN AMERICA: RECESSION IMPACT
             10.5.2 BRAZIL
                        10.5.2.1 Developed healthcare infrastructure and unified public health system to fuel market growth
                                      TABLE 220 BRAZIL: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)
                                      TABLE 221 BRAZIL: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
                                      TABLE 222 BRAZIL: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
                                      TABLE 223 BRAZIL: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2022–2029 (USD BILLION)
             10.5.3 REST OF LATIN AMERICA
                        TABLE 224 REST OF LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)
                        TABLE 225 REST OF LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
                        TABLE 226 REST OF LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
                        TABLE 227 REST OF LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2022–2029 (USD BILLION)
     10.6 MIDDLE EAST 
             TABLE 228 MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET, BY REGION, 2022–2029 (USD BILLION)
             TABLE 229 MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)
             TABLE 230 MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
             TABLE 231 MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
             TABLE 232 MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2022–2029 (USD BILLION)
             10.6.1 MIDDLE EAST: RECESSION IMPACT
             10.6.2 GCC COUNTRIES
                        TABLE 233 GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
                        TABLE 234 GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)
                        TABLE 235 GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
                        TABLE 236 GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
                        TABLE 237 GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2022–2029 (USD BILLION)
                        10.6.2.1 Saudi Arabia
                                     10.6.2.1.1 Increasing focus on R&D and growing government support to spur market growth
                                                      TABLE 238 SAUDI ARABIA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)
                                                      TABLE 239 SAUDI ARABIA: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
                                                      TABLE 240 SAUDI ARABIA: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
                                                      TABLE 241 SAUDI ARABIA: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2022–2029 (USD BILLION)
                        10.6.2.2 UAE
                                     10.6.2.2.1 Technological advancements and increased government focus on healthcare to support market growth
                                                      TABLE 242 UAE: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)
                                                      TABLE 243 UAE: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
                                                      TABLE 244 UAE: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
                                                      TABLE 245 UAE: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2022–2029 (USD BILLION)
                        10.6.2.3 Rest of GCC Countries
                                      TABLE 246 REST OF GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)
                                      TABLE 247 REST OF GCC COUNTRIES: IMMUNOTHERAPY DRUGS, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
                                      TABLE 248 REST OF GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
                                      TABLE 249 REST OF GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2022–2029 (USD BILLION)
             10.6.3 REST OF MIDDLE EAST
                        TABLE 250 REST OF MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)
                        TABLE 251 REST OF MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
                        TABLE 252 REST OF MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
                        TABLE 253 REST OF MIDDLE EAST: IMMUNOTHERAPY DRUGS THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD BILLION)
     10.7 AFRICA 
             10.7.1 INCREASING HEALTHCARE FUNDING AND RISING INCIDENCE OF CANCER TO DRIVE MARKET
                        TABLE 254 AFRICA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)
                        TABLE 255 AFRICA: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
                        TABLE 256 AFRICA: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
                        TABLE 257 AFRICA: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2022–2029 (USD BILLION)
             10.7.2 AFRICA: RECESSION IMPACT
 
11 COMPETITIVE LANDSCAPE (Page No. - 239)
     11.1 INTRODUCTION 
     11.2 KEY PLAYER STRATEGY/RIGHT TO WIN 
             11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN IMMUNOTHERAPY DRUGS MARKET
                        TABLE 258 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN IMMUNOTHERAPY DRUGS MARKET
     11.3 REVENUE ANALYSIS 
             FIGURE 31 REVENUE ANALYSIS OF KEY PLAYERS IN IMMUNOTHERAPY DRUGS MARKET (2021–2023)
     11.4 MARKET SHARE ANALYSIS 
             FIGURE 32 MARKET SHARE ANALYSIS OF KEY PLAYERS IN IMMUNOTHERAPY DRUGS MARKET (2023)
             TABLE 259 IMMUNOTHERAPY DRUGS MARKET: DEGREE OF COMPETITION
     11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 
             11.5.1 STARS
             11.5.2 EMERGING LEADERS
             11.5.3 PERVASIVE PLAYERS
             11.5.4 PARTICIPANTS
                        FIGURE 33 IMMUNOTHERAPY DRUGS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
             11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
                        11.5.5.1 Company footprint
                                      FIGURE 34 IMMUNOTHERAPY DRUGS MARKET: COMPANY FOOTPRINT
                        11.5.5.2 Type footprint
                                      TABLE 260 IMMUNOTHERAPY DRUGS MARKET: TYPE FOOTPRINT
                        11.5.5.3 Application footprint
                                      TABLE 261 IMMUNOTHERAPY DRUGS MARKET: APPLICATION FOOTPRINT
                        11.5.5.4 Route of administration footprint
                                      TABLE 262 IMMUNOTHERAPY DRUGS MARKET: ROUTE OF ADMINISTRATION FOOTPRINT
                        11.5.5.5 Region footprint
                                      TABLE 263 IMMUNOTHERAPY DRUGS MARKET: REGION FOOTPRINT
     11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 
             11.6.1 PROGRESSIVE COMPANIES
             11.6.2 RESPONSIVE COMPANIES
             11.6.3 DYNAMIC COMPANIES
             11.6.4 STARTING BLOCKS
                        FIGURE 35 IMMUNOTHERAPY DRUGS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
             11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
                        TABLE 264 IMMUNOTHERAPY DRUGS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
                        TABLE 265 IMMUNOTHERAPY DRUGS MARKET: COMPETITIVE BENCHMARKING OF KEY START UPS/SMES
     11.7 COMPANY VALUATION & FINANCIAL METRICS 
             FIGURE 36 EV/EBITDA OF KEY PLAYERS
             FIGURE 37 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY PLAYERS
     11.8 BRAND/PRODUCT COMPARISON 
             FIGURE 38 IMMUNOTHERAPY DRUGS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
     11.9 COMPETITIVE SCENARIO 
             11.9.1 PRODUCT APPROVALS
                        TABLE 266 IMMUNOTHERAPY DRUGS MARKET: PRODUCT APPROVALS, JANUARY 2021–MAY 2024
             11.9.2 DEALS
                        TABLE 267 IMMUNOTHERAPY DRUGS MARKET: DEALS, JANUARY 2021–MAY 2024
             11.9.3 OTHER DEVELOPMENTS
                        TABLE 268 IMMUNOTHERAPY DRUGS MARKET: OTHER DEVELOPMENTS, JANUARY 2021–MAY 2024
 
12 COMPANY PROFILES (Page No. - 259)
(Business Overview, Products/Solutions/Services Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
     12.1 KEY PLAYERS 
             12.1.1 MERCK & CO., INC.
                        TABLE 269 MERCK & CO., INC.: COMPANY OVERVIEW
                        FIGURE 39 MERCK & CO., INC.: COMPANY SNAPSHOT (2023)
                        TABLE 270 MERCK & CO., INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
                        TABLE 271 MERCK & CO., INC.: PRODUCT APPROVALS, JANUARY 2021–MAY 2024
                        TABLE 272 MERCK & CO., INC.: DEALS, JANUARY 2021–MAY 2024
             12.1.2 JOHNSON & JOHNSON SERVICES, INC.
                        TABLE 273 JOHNSON & JOHNSON SERVICES, INC.: COMPANY OVERVIEW
                        FIGURE 40 JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT (2023)
                        TABLE 274 JOHNSON & JOHNSON SERVICES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
                        TABLE 275 JOHNSON & JOHNSON SERVICES, INC.: PRODUCT APPROVALS, JANUARY 2021–MAY 2024
                        TABLE 276 JOHNSON & JOHNSON SERVICES, INC.: DEALS, JANUARY 2021–MAY 2024
                        TABLE 277 JOHNSON & JOHNSON SERVICES, INC.: EXPANSIONS, JANUARY 2021–MAY 2024
             12.1.3 F. HOFFMANN-LA ROCHE LTD.
                        TABLE 278 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
                        FIGURE 41 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2023)
                        TABLE 279 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
                        TABLE 280 F. HOFFMANN-LA ROCHE LTD.: PRODUCT APPROVALS, JANUARY 2021–MAY 2024
                        TABLE 281 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2021–MAY 2024
             12.1.4 ASTRAZENECA
                        TABLE 282 ASTRAZENECA: COMPANY OVERVIEW
                        FIGURE 42 ASTRAZENECA: COMPANY SNAPSHOT (2023)
                        TABLE 283 ASTRAZENECA: PRODUCTS/SERVICES/SOLUTIONS OFFERED
                        TABLE 284 ASTRAZENECA: PRODUCT APPROVALS, JANUARY 2021–MAY 2024
                        TABLE 285 ASTRAZENECA: DEALS, JANUARY 2021–MAY 2024
                        TABLE 286 ASTRAZENECA: EXPANSIONS, JANUARY 2021–MAY 2024
             12.1.5 PFIZER INC.
                        TABLE 287 PFIZER INC.: COMPANY OVERVIEW
                        FIGURE 43 PFIZER INC.: COMPANY SNAPSHOT (2023)
                        TABLE 288 PFIZER INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
                        TABLE 289 PFIZER INC.: PRODUCT APPROVALS, JANUARY 2021–MAY 2024
                        TABLE 290 PFIZER INC.: DEALS, JANUARY 2021–MAY 2024
             12.1.6 AMGEN INC.
                        TABLE 291 AMGEN INC.: COMPANY OVERVIEW
                        FIGURE 44 AMGEN INC.: COMPANY SNAPSHOT (2023)
                        TABLE 292 AMGEN INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
                        TABLE 293 AMGEN INC.: PRODUCT APPROVALS, JANUARY 2021–MAY 2024
                        TABLE 294 AMGEN INC.: EXPANSIONS, JANUARY 2021–MAY 2024
             12.1.7 NOVARTIS AG
                        TABLE 295 NOVARTIS AG: COMPANY OVERVIEW
                        FIGURE 45 NOVARTIS AG: COMPANY SNAPSHOT (2023)
                        TABLE 296 NOVARTIS AG: PRODUCTS/SERVICES/SOLUTIONS OFFERED
                        TABLE 297 NOVARTIS AG: PRODUCT APPROVALS, JANUARY 2021–MAY 2024
                        TABLE 298 NOVARTIS AG: DEALS, JANUARY 2021–MAY 2024
             12.1.8 ELI LILLY AND COMPANY
                        TABLE 299 ELI LILLY AND COMPANY: COMPANY OVERVIEW
                        FIGURE 46 ELI LILLY AND COMPANY.: COMPANY SNAPSHOT (2023)
                        TABLE 300 ELI LILLY AND COMPANY: PRODUCTS/SERVICES/SOLUTIONS OFFERED
                        TABLE 301 ELI LILLY AND COMPANY: PRODUCT APPROVALS, JANUARY 2021–MAY 2024
                        TABLE 302 ELI LILLY AND COMPANY.: DEALS, JANUARY 2021–MAY 2024
             12.1.9 SANOFI
                        TABLE 303 SANOFI: COMPANY OVERVIEW
                        FIGURE 47 SANOFI: COMPANY SNAPSHOT (2023)
                        TABLE 304 SANOFI: PRODUCTS/SERVICES/SOLUTIONS OFFERED
                        TABLE 305 SANOFI: PRODUCT APPROVALS, JANUARY 2021–MAY 2024
                        TABLE 306 SANOFI: DEALS, JANUARY 2021–MAY 2024
             12.1.10 BRISTOL-MYERS SQUIBB COMPANY
                        TABLE 307 BRISTOL-MYERS SQUIBB COMPANY: COMPANY OVERVIEW
                        FIGURE 48 BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT (2023)
                        TABLE 308 BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS/SERVICES/SOLUTIONS OFFERED
                        TABLE 309 BRISTOL-MYERS SQUIBB COMPANY: PRODUCT APPROVALS, JANUARY 2021–MAY 2024
                        TABLE 310 BRISTOL-MYERS SQUIBB COMPANY: DEALS, JANUARY 2021–MAY 2024
             12.1.11 GILEAD SCIENCES, INC.
                        TABLE 311 GILEAD SCIENCES, INC.: COMPANY OVERVIEW
                        FIGURE 49 GILEAD SCIENCES, INC.: COMPANY SNAPSHOT (2023)
                        TABLE 312 GILEAD SCIENCES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
                        TABLE 313 GILEAD SCIENCES, INC.: PRODUCT APPROVALS, JANUARY 2021–MAY 2024
                        TABLE 314 GILEAD SCIENCES, INC.: DEALS, JANUARY 2021–MAY 2024
                        TABLE 315 GILEAD SCIENCES, INC.: OTHER DEVELOPMENTS, JANUARY 2021–MAY 2024
             12.1.12 TAKEDA PHARMACEUTICAL COMPANY LIMITED
                        TABLE 316 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY OVERVIEW
                        FIGURE 50 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2023)
                        TABLE 317 TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCTS/SERVICES/SOLUTIONS OFFERED
                        TABLE 318 TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT APPROVALS, JANUARY 2021–MAY 2024
                        TABLE 319 TAKEDA PHARMACEUTICAL COMPANY LIMITED: DEALS, JANUARY 2021–MAY 2024
             12.1.13 TEVA PHARMACEUTICAL INDUSTRIES LTD.
                        TABLE 320 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW
                        FIGURE 51 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2023)
                        TABLE 321 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
                        TABLE 322 TEVA PHARMACEUTICAL INDUSTRIES LTD.: DEALS, JANUARY 2021–MAY 2024
             12.1.14 ABBVIE INC.
                        TABLE 323 ABBVIE INC.: COMPANY OVERVIEW
                        FIGURE 52 ABBVIE INC.: COMPANY SNAPSHOT (2023)
                        TABLE 324 ABBVIE INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
                        TABLE 325 ABBVIE INC.: PRODUCT APPROVALS, JANUARY 2021–MAY 2024
                        TABLE 326 ABBVIE INC.: DEALS, JANUARY 2021–MAY 2024
             12.1.15 GSK PLC
                        TABLE 327 GSK PLC: COMPANY OVERVIEW
                        FIGURE 53 GSK PLC: COMPANY SNAPSHOT (2023)
                        TABLE 328 GSK PLC: PRODUCTS/SERVICES/SOLUTIONS OFFERED
                        TABLE 329 GSK PLC: PRODUCT APPROVALS, JANUARY 2021–MAY 2024
                        TABLE 330 GSK PLC: DEALS, JANUARY 2021–MAY 2024
                        TABLE 331 GSK PLC: OTHER DEVELOPMENTS, JANUARY 2021–MAY 2024
     12.2 OTHER PLAYERS 
             12.2.1 IMMUNOCORE HOLDINGS PLC
                        TABLE 332 IMMUNOCORE HOLDINGS PLC: COMPANY OVERVIEW
             12.2.2 ASTELLAS PHARMA INC.
                        TABLE 333 ASTELLAS PHARMA INC.: COMPANY OVERVIEW
             12.2.3 GENMAB A/S
                        TABLE 334 GENMAB A/S: COMPANY OVERVIEW
             12.2.4 MACROGENICS, INC.
                        TABLE 335 MACROGENICS, INC.: COMPANY OVERVIEW
             12.2.5 FERRING BV
                        TABLE 336 FERRING BV: COMPANY OVERVIEW
             12.2.6 Y-MABS THERAPEUTICS, INC.
                        TABLE 337 Y-MABS THERAPEUTICS, INC.: COMPANY OVERVIEW
             12.2.7 BIOGEN
                        TABLE 338 BIOGEN: COMPANY OVERVIEW
             12.2.8 KYOWA KIRIN CO., LTD.
                        TABLE 339 KYOWA KIRIN CO., LTD.: COMPANY OVERVIEW
             12.2.9 SWEDISH ORPHAN BIOVITRUM AB
                        TABLE 340 SWEDISH ORPHAN BIOVITRUM AB: COMPANY OVERVIEW
             12.2.10 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
                        TABLE 341 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY OVERVIEW
 
*Details on Business Overview, Products/Solutions/Services Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
 
13 APPENDIX (Page No. - 342)
     13.1 DISCUSSION GUIDE 
     13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     13.3 CUSTOMIZATION OPTIONS 
     13.4 RELATED REPORTS 
     13.5 AUTHOR DETAILS 

This study involved four major activities in estimating the current size of the immunotherapy drugs market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the immunotherapy drugs market. The secondary sources referred to for this research study include publications from government sources, such as National Institutes of Health (NIH), United States Food and Drug Administration (US FDA), World Health Organization (WHO), European Pharmaceutical Review, American Society of Gene & Cell Therapy (ASGCT), European Society of Gene and Cell Therapy (ESGCT), European Medicines Agency (EMA), and the Alliance for Regenerative Medicine (ARM). Secondary sources also include corporate and regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines and research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the immunotherapy drugs market, which was validated through primary research. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

Primary Research

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess the prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information.

Immunotherapy Drugs Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The global size of the immunotherapy drugs market was estimated through multiple approaches. A detailed market estimation approach was followed to estimate and validate the value of the immunotherapy drugs and other dependent submarkets. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and markets have been identified through extensive secondary research
  • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Immunotherapy Drugs Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Data Triangulation

After arriving at the overall market size—using the market size estimation processes—the market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics of each market segment, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the immunotherapy drugs market.

Market Definition

Immunotherapy drugs are a broad category of therapeutic agents that help stimulate the body's immune system to combat diseases. These drugs include antibody therapies, cell & gene therapy, inhibitor drugs, and other drugs such as oncolytic viral therapy and cancer vaccines. These drugs are engineered to enhance the immune response or counteract the immune system's regulatory mechanisms, thereby enabling the body to effectively target and eliminate disease-causing agents or cells. Immunotherapy drugs are used to treat various medical conditions, including cancer, autoimmune diseases, hematology, osteology, neurology, and other therapy areas (such as ophthalmology, dermatology, and cardiovascular disorders).

Stakeholders

  • Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Venture Capitalists and Investors
  • Contract Development & Manufacturing Organizations
  • Government Associations
  • Healthcare Associations/Institutes
  • Business Research & Consulting Service Providers

Report Objectives

  • To define, describe, and forecast the immunotherapy market based on type,  application, route of administrration, end user, and region
  • To provide detailed information about the drivers, restraints, opportunities, and challenges influencing the market growth
  • To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall immunotherapy drugs market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of market segments in North America, Europe, the Asia Pacific (APAC), Latin America, Middle East and Africa
  • To profile the key players and comprehensively analyze their core competencies2 in terms of key developments, product portfolios, and financials
  • To track and analyze competitive developments, such as partnerships, collaborations, agreements, and acquisitions, in the immunotherapy drugs market
  • Micromarkets are the further segments and subsegments of the immunotherapy drugs market.
  • Core competencies of companies are captured in terms of the key developments, market shares, and key strategies adopted to sustain their positions in the market.

Available Customizations:

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

  • Company Information: Detailed analysis and profiling of additional market players (up to five)
  • Geographic Analysis: Further breakdown of the Rest of Europe market, by country, based on approvals and feasibility. Further breakdown of the Rest of Asia Pacific market, by country, based on approvals and feasibility
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
PH 3926
Published ON
Jul, 2024
REQUEST FREE SAMPLE REPORT
Choose License Type
BUY NOW
Inquire Before Buying
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Immunotherapy Drugs Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback